A key tariff exemption considers a drug's origin to be where its Active Pharmaceutical Ingredient (API) was made. This allows companies to manufacture an API in the US, export it for final formulation, and then re-import the finished product tariff-free, offering a significant supply chain strategy to bypass import taxes.

The steep tariff on foreign-made drugs is an aggressive tactic to compel pharmaceutical companies to bring manufacturing back to the US. It aims to solve two critical problems: reducing strategic dependency on adversaries like China and rebuilding domestic manufacturing jobs.

The current pharma tariffs are based on a "national security provision" (Section 232), which has a more secure legal footing than prior, successfully challenged tariff orders. Drawing parallels to long-standing steel and China tariffs, companies should strategize for this as a permanent feature of the trade landscape, not a temporary policy.

Effective tariff reduction requires a deep dive into three fundamental customs compliance areas: country of origin rules, correct tariff code classification, and customs valuation methods. Experts suggest the biggest savings opportunities for many firms lie in scrutinizing and optimizing these often-overlooked details to legitimately lower their dutiable base.

The biopharma outsourcing sector has proven surprisingly resilient to international tariffs. Instead of absorbing costs, well-funded European companies are bypassing tariffs altogether by investing in and building new production facilities directly on U.S. soil, effectively onshoring their manufacturing.

To achieve Most Favored Nation (MFN) drug pricing, the administration paired HHS negotiators with the Commerce Secretary. While one team negotiated terms, the Commerce Secretary acted as the "hammer," holding a credible threat of crippling tariffs over pharmaceutical companies that primarily manufacture overseas. This forced compliance.

In response to unpredictable global tariffs, Hasbro invests in tooling manufacturing lines in multiple countries simultaneously. This strategy increases initial costs but provides the flexibility to shift production and avoid exposure to any single region's policies.

The administration's proposed 100% tariffs on some pharma companies are more political posturing than substantive policy. The tariffs exclude generics, orphan drugs, and rare disease treatments. Additionally, 16 of the 17 largest pharma companies have already signed deals with the U.S., making them exempt.

The proposed pharma tariffs exempt companies with MFN (Most Favored Nation) deals, which are primarily large players. This gives them a strategic advantage in M&A, as they can acquire smaller, tariff-burdened companies and absorb their assets into a tariff-free structure, creating favorable deal dynamics.